Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity
1996

Silibinin Protects Against Kidney Damage from Cisplatin

Sample size: 45 publication Evidence: moderate

Author Information

Author(s): C Bokemeyer, LM Fels, T Dunn, W Voigt, J Gaedeke, H-J Schmoll, H Stolte, H Lentzen

Primary Institution: University of Tübingen

Hypothesis

Can silibinin protect against cisplatin-induced nephrotoxicity without affecting its anti-tumor activity?

Conclusion

Silibinin effectively reduces kidney toxicity caused by cisplatin while preserving its anti-tumor effects.

Supporting Evidence

  • Silibinin significantly decreased kidney toxicity indicators in rats treated with cisplatin.
  • Creatinine clearance was notably reduced in rats treated with cisplatin alone compared to those treated with silibinin and cisplatin.
  • Urinary excretion of brush-border enzymes was significantly lower in the silibinin group.

Takeaway

Silibinin is like a shield for your kidneys when taking a strong medicine called cisplatin, helping to keep them safe while still fighting cancer.

Methodology

The study used a rat model to assess kidney function after administering silibinin and cisplatin, measuring various urinary and serum parameters.

Limitations

The study was conducted in a rat model, which may not fully replicate human responses.

Participant Demographics

Female Wistar rats aged between 170 and 230 g.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication